Vaccine Adjuvants Market is projected to grow from USD 1.5 billion in 2022 to USD 1.6 billion by 2027, at a CAGR of 1.7% from 2022 to 2027, according to a new report by MarketsandMarkets™. The growth of the market is projected to be driven by collaborations and partnerships among market players for the development of vaccine adjuvants, an increasing number of COVID-19 vaccines in the development pipeline and increasing focus on immunization programs.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
Browse in-depth TOC on “Vaccine Adjuvants Market”
191 – Tables
44 – Figures
214 – Pages
Key Market Players
Key players in the vaccine adjuvants market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).
Vaccine Adjuvants Market Dynamics
Drivers: Rising prevalence of infectious diseases
The prevalence of infectious diseases, such as influenza, tuberculosis, malaria, and HIV, among others, has increased. The WHO estimates that seasonal influenza results in ~3 to 5 million cases of severe illness and ~290,000 to 650,000 respiratory deaths each year. In this regard, national influenza centers (NICs) and other national influenza laboratories from 74 countries have reported that the Global Influenza Surveillance and Response System (GISRS) laboratories tested more than 204,655 specimens for influenza between January 20, 2020, and February 20, 2020. Of these specimens, ~29% were found to be positive for the influenza virus. Influenza is one of the most common infectious diseases in the US.
Restraints: Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing
Squalene, derived from shark liver oil, is used in some adjuvants. This has led to the overfishing of sharks. As per the conservationist group Shark Allies, nearly 250,000 sharks need to be killed for the development of one COVID-19 vaccine dose for the global population.
Opportunities: Rising funding for vaccines and infectious disease research activities
With the emergence of COVID-19, government authorities and pharmaceutical & biotechnology companies have recognized the importance of research on infectious diseases. In June 2022, the US announced a funding of USD 122 million to top Indian medical research institutes to prevent avoidable epidemics, early detection of disease threats, and rapid and effective response.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894
Challenges: Side effects and high toxicity of adjuvants
Vaccine adjuvants have various limitations, such as side effects and high toxicity, which are the major challenges hindering market growth. For instance, aluminum-based adjuvants have mild reactions after injection. Frequent occurrence of granulomas results in an increase in IgE production, and high levels of these salts cause neurological disorders and dialysis-associated dementia.
The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets of the region is drive by increasing investments in the life sciences sector and rising awareness through conferences & symposiums, and growing emphasis on strategic initiatives such as partnerships, and collaborations by biopharma and biotech companies.
- Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.
- SK Bioscience (South Korea)and GSK plc (UK)entered into a collaboration for COVID-19 vaccine development.
Enquiry Before Buying this Report : https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=152603894
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062